Company Description
Tempus AI endeavors to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence in healthcare.
Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
To accomplish this, we built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful.
Our proprietary technology has allowed us to amass what we consider to be one of the largest libraries of clinical and molecular oncology data in the world.
We have launched a suite of different products derived from our Platform, which have gained significant traction over the past five years.
To date, our offerings have been used by approximately 95% of the largest public pharmaceutical companies.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 14, 2024 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,300 |
| CEO | Eric Lefkofsky |
Contact Details
Address: 600 West Chicago Avenue, Suite 510 Chicago, IL 60654 United States | |
| Phone | (800) 976-5448 |
| Website | tempus.com |
Stock Details
| Ticker Symbol | TEM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $37.00 |
| CIK Code | 0001717115 |
| Employer ID | 47-4903308 |
| SIC Code | 7370 |
Key Executives
| Name | Position |
|---|---|
| Eric Lefkofsky | Chief Executive Officer, Founder and Director |
| Ryan Fukushima | Chief Operating Officer |
| Erik Phelps | Executive Vice President, Chief Administrative and Legal Officer and Assistant Secretary |
| Andrew Polovin | Executive Vice President, General Counsel and Secretary |
| James Rogers | Chief Financial Officer |
| Peter J. Barris | Director |
| Eric D. Belcher | Director |
| Jennifer A. Doudna, Ph.D. | Director |
| David R. Epstein | Director |
| Wayne A.I. Frederick, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 17, 2024 | 8-K | Current Report |
| Jun 17, 2024 | 424B4 | Prospectus |
| Jun 13, 2024 | EFFECT | Notice of Effectiveness |
| Jun 13, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 12, 2024 | CERT | Certification by an exchange approving securities for listing |
| Jun 11, 2024 | 8-A12B | Registration of securities |
| Jun 5, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 20, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Feb 28, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |